Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04947423 · ClinicalTrials.gov registry record · Phase 3
Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion
A Phase 3 study, sponsored by Repurposed Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 140
- Enrollment target
NCT04947423 is a Phase 3 study that has completed, run by Repurposed Therapeutics. The registered enrollment target is 140 participants.
The verdict
NCT04947423, a Phase 3 study, has completed, sponsored by Repurposed Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 140 participants
- Enrollment target
Study Summary
This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion
Interventions
- DRUG Placebo
- DRUG DPI-386 Nasal Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2021-06-14 |
| Est. Completion | 2021-08-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04947423
The ClinicalTrials.gov registry entry for NCT04947423 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repurposed Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04947423 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04947423 about?
NCT04947423 is a clinical study titled "Nasal Gel for the Prevention of Nausea and Vomiting Associated With Motion". This is a Phase 3, two-arm, randomized, double-blind, placebo-controlled, single dose efficacy and safety study evaluating the use of a nasal gel to prevent nausea and vomiting associated with motion
What is the current status of trial NCT04947423?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 140 participants. The study started on 2021-06-14. Estimated completion is 2021-08-12.
What interventions are being tested in trial NCT04947423?
The interventions under investigation include: Placebo (DRUG), DPI-386 Nasal Gel (DRUG).
Who is sponsoring clinical trial NCT04947423?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.